A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients (Q33977510)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Jin Mo Yang

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Byung Ik Kim

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Soon Koo Baik

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gab Jin Cheon

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Kwan Soo Byun

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Do Young Kim

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Byung Chul Yoo

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

25 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hepatology international

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

375-381

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

copyright license

Creative Commons Attribution 4.0 International

25 May 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Personal view: the management of chronic hepatitis B infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Management of hepatitis B patients with antiviral resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

5 July 2018

The association of hepatitis B with primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9537-5

21 January 2018

Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4116600

29 October 2018

Identifiers

10.1007/S12072-014-9537-5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25101150%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33977510&oldid=2196079333"